Penumbra (PEN) Liabilities and Shareholders Equity (2014 - 2026)
Penumbra (PEN) posted quarterly Liabilities and Shareholders Equity of $2.0 billion for Q2 2026, up 17.91% year-over-year from $1.7 billion in Q2 2025, and up 4.02% quarter-over-quarter from $1.9 billion in Q1 2026.
Penumbra (PEN) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends
Penumbra (PEN) has reported Liabilities and Shareholders Equity for 13 consecutive years, with $2.0 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Liabilities and Shareholders Equity rose 17.91% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $7.4 billion (up 18.53% YoY), while the FY2025 annual figure was $1.8 billion, up 19.13% from the prior year.
- Liabilities and Shareholders Equity climbed to $2.0 billion in Q2 2026 per PEN's latest filing, from $1.9 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $2.0 billion in Q2 2026 and bottomed at $1.3 billion in Q1 2022.
- Historically, Liabilities and Shareholders Equity has averaged $1.6 billion across 5 years, with a median of $1.5 billion in 2024.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 54.8% — and 2024, when it retreated 1.49%.
- Penumbra's Liabilities and Shareholders Equity stood at $1.4 billion in 2022, then advanced by 13.53% to $1.6 billion in 2023, then retreated by 1.49% to $1.5 billion in 2024, then gained by 19.13% to $1.8 billion in 2025, then grew by 8.11% to $2.0 billion in 2026.
- Business Quant data shows PEN's Liabilities and Shareholders Equity at $2.0 billion in Q2 2026, $1.9 billion in Q1 2026, and $1.8 billion in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.95 Bn | 193.35 Bn | 7.27 Bn | 109.22 Bn |
| 2 | Stryker | 128.10 Bn | 124.63 Bn | 4.50 Bn | 47.93 Bn |
| 3 | Medtronic | 118.91 Bn | 109.69 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 73.43 Bn | 72.89 Bn | 3.85 Bn | 45.22 Bn |
| 5 | Edwards Lifesciences | 51.91 Bn | 47.66 Bn | 1.35 Bn | 13.87 Bn |
| 6 | Dexcom | 34.52 Bn | 32.58 Bn | 830.00 Mn | 6.46 Bn |
| 7 | GE HealthCare Technologies | 33.94 Bn | 31.83 Bn | 2.18 Bn | 37.25 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 31.04 Bn |
| 9 | Steris | 23.14 Bn | 22.66 Bn | 684.20 Mn | 10.74 Bn |
| 10 | Penumbra | 12.79 Bn | 12.13 Bn | 264.94 Mn | 1.97 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.97 Bn |
| Mar 31, 2026 | 1.90 Bn |
| Dec 31, 2025 | 1.83 Bn |
| Sep 30, 2025 | 1.74 Bn |
| Jun 30, 2025 | 1.67 Bn |
| Mar 31, 2025 | 1.59 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.48 Bn |
| Jun 30, 2024 | 1.53 Bn |
| Mar 31, 2024 | 1.58 Bn |
| Dec 31, 2023 | 1.56 Bn |
| Sep 30, 2023 | 1.47 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 1.40 Bn |
| Dec 31, 2022 | 1.37 Bn |
| Sep 30, 2022 | 1.32 Bn |
| Jun 30, 2022 | 1.33 Bn |
| Mar 31, 2022 | 1.30 Bn |
| Dec 31, 2021 | 1.24 Bn |
| Sep 30, 2021 | 973.24 Mn |